BioNTech Results Presentation Deck

BNT311: Phase 2 Trial Targeting CPI-experienced PD-L1+ R/R NSCLC ● ***** Stage IV metastatic R/R NSCLC (2L+) PD-L1 TPS ≥1% 20 R FPD in December 2021 N-130 Primary Endpoints 1:1:1 ORR per RECIST 1.1 Standard of Care Benchmark 2 Docetaxel, ORR: 4-15% ² A: BNT311 monotherapy Open-label, randomized Phase 2 trial BNT311 as monotherapy and in combination with Pembrolizumab after treatment with SOC immune checkpoint inhibitor B*: BNT311+ pembrolizumab C*: BNT311 + pembrolizumab (alternative treatment schedule) Secondary Endpoints • PFS • DOR Significant unmet need in R/R NSCLC ~1.8 million lung cancer deaths worldwide annually¹ NSCLC is most common type (~85%) ² 5-year survival only 4% for advanced or metastatic. NSCLC3 CPI therapy fails in majority of NSCLC patients due to evolution of resistance Poor prognosis for CPI R/R NSCLC Estimated PFS of < 6 months and OS of <1 year ● New strategies needed to overcome resistance and maximize efficacy Partnered with Genmab; 50:50 profit/loss collaboration R/R, refractory/relapsed; NSCLC, non-small cell lung cancer; PD-L1, programmed death-ligand 1; SOC, Standard of Care; CPI, check point inhibitor; TPS, tumor proportion score; ORR; objective response rate; PFS, progression free survival; DoR, duration of response; OS, Overall Survival *Following Safety run-in ¹Bray et al., 2018; 2https://www.cancer.net/cancer-types/lung-cancer-non-small-cell/statistics; Cancer statistics, 2018.Siegel et al., CA Cancer J Clin. 2018 Jan; 68(1):7-30 2Qu et al., 2022; https://journals.sagepub.com/doi/10.1177/1758835921992968 BIONTECH Y

View entire presentation